Watch for Injectable Semaglutide to Treat Fatty Liver
April 2026
Injectable semaglutide is the first GLP-1 agonist FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) treatment.
About 15 million adults in the US have MASH...and it’s on the rise.
MASH is when fat builds up in the liver...leading to inflammation and liver damage. If left untreated, it can progress to fibrosis (or scarring), cirrhosis (severe scarring), liver failure, or even death.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote